̽»¨¾«Ñ¡

Antti Mustonen

Antti Mustonen

Anknuten till Forskning
E-postadress: antti.mustonen@ki.se
µþ±ð²õö°ì²õ²¹»å°ù±ð²õ²õ: Avd försäkringsmedicin, ̽»¨¾«Ñ¡, 17177 Stockholm
Postadress: K8 Klinisk neurovetenskap, K8 Fm Mittendorfer-Rutz, 171 77 Stockholm

Artiklar

  • Article: BRITISH JOURNAL OF PSYCHIATRY. 2025;:1-7
    Mustonen A; Taipale H; Denissoff A; Ellila V; Di Forti M; Tanskanen A; Mittendorfer-Rutz E; Tiihonen J; Niemelae S
  • Journal article: EUROPEAN PSYCHIATRY. 2025;68(Suppl 1):s14-s15
    Niemelä S; Denissoff A; Sassi P; Mustonen A; Mittendorfer-Rutz E; Tiihonen J; Taipale H
  • Article: SCHIZOPHRENIA BULLETIN. 2024;50(6):1287-1294
    Denissoff A; Taipale H; Tiihonen J; Di Forti M; Mittendorfer-Rutz E; Tanskanen A; Mustonen A; Niemela S
  • Journal article: BMC PUBLIC HEALTH. 2024;24(1):255
    Levola J; Alakokkare A-E; Denissoff A; Mustonen A; Miettunen J; Niemela S
  • Journal article: EUROPEAN JOURNAL OF PUBLIC HEALTH. 2023;33(6):1115-1121
    Koivisto MK; Puljula J; Levola JM; Mustonen A; Miettunen J; Alakokkare A-E; Niemelae S
  • Journal article: JOURNAL OF SUBSTANCE USE. 2023;28(5):704-707
    Penttala J; Mustonen A; Koivukangas A; Halme J; Karjalainen K; Aalto M
  • Journal article: ACTA PSYCHIATRICA SCANDINAVICA. 2023;148(3):277-287
    Mustonen A; Rodriguez A; Scott JGG; Vuori M; Hurtig T; Halt A-H; Miettunen J; Alakokkare A-E; Niemela S
  • Journal article: JOURNAL OF STUDIES ON ALCOHOL AND DRUGS. 2023;84(2):198-207
    Levola J; Denisoff A; Mustonen A; Alakokkare A-E; Miettunen J; Bramness JG; Niemelae S
  • Journal article: NORDIC JOURNAL OF PSYCHIATRY. 2023;77(2):165-171
    Mustonen A; Alakokkare A-E; Scott JG; Halt A-H; Vuori M; Hurtig T; Rodriguez A; Miettunen J; Niemela S
  • Journal article: CURRENT ADDICTION REPORTS. 2022;9(4):598-607
    Denissoff A; Levola J; Niemela S; Mustonen A
  • Journal article: ACTA PSYCHIATRICA SCANDINAVICA. 2022;146(6):594-603
    Bolstad I; Alakokkare A-E; Bramness JG; Rognli EB; Levola J; Mustonen A; Miettunen J; Niemela S
  • Journal article: EUROPEAN JOURNAL OF PUBLIC HEALTH. 2022;32(5):753-759
    Koivisto MK; Miettunen J; Levola J; Mustonen A; Alakokkare A-E; Salom CL; Niemela S
  • Journal article: JOURNAL OF ADOLESCENCE. 2022;94(7):996-1007
    Sarala M; Miettunen J; Alakokkare A-E; Mustonen A; Scott JG; Thomas HJ; Hurtig T; Niemela S
  • Journal article: SCHIZOPHRENIA RESEARCH. 2022;246:95-102
    Denissoff A; Mustonen A; Miettunen J; Alakokkare A-E; Veijola J; Scott JG; Sami MB; Niemela S
  • Journal article: ADDICTION. 2022;117(8):2264-2272
    Denissoff A; Mustonen A; Alakokkare A-E; Scott JG; Sami MB; Miettunen J; Niemela S
  • Journal article: EUROPEAN JOURNAL OF PUBLIC HEALTH. 2022;32(2):254-260
    Sarala M; Mustonen A; Alakokkare A-E; Salom C; Miettunen J; Niemela S
  • Journal article: ACTA PSYCHIATRICA SCANDINAVICA. 2022;145(3):234-243
    Denissoff A; Niemela S; Scott JG; Salom CL; Hielscher E; Miettunen J; Alakokkare A-E; Mustonen A
  • Journal article: CASE REPORTS IN PSYCHIATRY. 2021;2021:1-4
    Mustonen A; Leijala J; Aronranta J; Lassila A; Aalto M; Koskimäki J
  • Journal article: BJPSYCH OPEN. 2021;7(4):e137
    Mustonen A; Hielscher E; Miettunen J; Denissoff A; Alakokkare A-E; Scott JG; Niemela S
  • Journal article: ADDICTIVE BEHAVIORS. 2021;118:106910
    Antti M; Anni-Emilia A; Caroline S; Tuula H; Jonna L; Scott JG; Jouko M; Solja N
  • Journal article: EUROPEAN JOURNAL OF PUBLIC HEALTH. 2020;30(6):1189-1193
    Levola J; Rose RJ; Mustonen A; Sarala M; Miettunen J; Koskela J; Niemela A-E; Niemela S
  • Journal article: JOURNAL OF ADOLESCENT HEALTH. 2020;67(5):692-699
    Levola J; Sarala M; Mustonen A; Rose RJ; Miettunen J; Niemela A-E; Niemela S
  • Journal article: BRITISH JOURNAL OF PSYCHIATRY. 2020;217(2):458
    Mustonen A; Niemela S; Nordstrom T; Murray GK; Jaaskelainen E; Miettunen J
  • Journal article: ADDICTION. 2020;115(5):888-900
    Sarala M; Miettunen J; Koskela J; Mustonen A; Rose RJ; Hurtig T; Veijola J; Niemela S
  • Journal article: FRONTIERS IN PSYCHIATRY. 2018;9:607
    Scott JG; Matuschka L; Niemela S; Miettunen J; Emmerson B; Mustonen A
  • Journal article: SCHIZOPHRENIA RESEARCH. 2018;201:360-366
    Mustonen A; Niemela S; McGrath JJ; Murray GK; Nordstrom T; Maki P; Miettunen J; Scott JG
  • Journal article: ACTA PSYCHIATRICA SCANDINAVICA. 2018;138(1):5-14
    Mustonen A; Ahokas T; Nordstrom T; Murray GK; Maki P; Jaaskelainen E; Heiskala A; Mcgrath JJ; Scott JG; Miettunen J; Niemela S
  • Journal article: BRITISH JOURNAL OF PSYCHIATRY. 2018;212(4):227-233
    Mustonen A; Niemela S; Nordstrom T; Murray GK; Maki P; Jaaskelainen E; Miettunen J
  • Visa fler

Alla övriga publikationer

  • Conference publication: SCHIZOPHRENIA BULLETIN. 2020;46:S168-S169
    Peltonen T; Mustonen A; Koskela J; Miettunen J; Veijola J; Niemela S
  • Conference publication: SCHIZOPHRENIA BULLETIN. 2020;46:S69
    Niemela S; Peltonen T; Koskela J; Mustonen A; Miettunen J; Hurtig T
  • Conference publication: EUROPEAN PSYCHIATRY. 2015;30:241
    Miettunen J; Kasurinen K; Paaso TM; Mustonen A; Hirvonen N; Oinas E; Kakela J; Jaaskelainen E

Forskningsbidrag

  • Swedish Research Council
    1 January 2025 - 31 December 2027
    Cannabis use is increasing worldwide and also certain European countries plan to legalize or decriminalize cannabis. This will further increase use rates and also result into higher number of people with cannabis use disorder. Cannabis use in persons with severe mental disorders, namely schizophrenia-spectrum disorders, bipolar disorders and major depressive disorder, has been reported to adversely impact on illness course and associate with non-adherence to treatments. However, impacts of cannabis use disorder on long-term treatment outcomes in severe mental disorders are not known.  The overall aim of this project is to investigate long-term treatment pathways and outcomes of patients with severe mental disorder and comorbid cannabis use disorder, to help in designing optimal health care for these patients. We aim to investigate healthcare service and medication use and work disability during first five years of illness, compared to patients with severe mental disorder without cannabis use disorder. We will also investigate risk of mortality and effectiveness of medications associated with decreased risk of illness relapse, and mortality. Finally, we will develop a prediction model for adverse clinical outcomes to help clinical practice to inform which patients are at the highest risk and in need of enhanced monitoring and effective interventions. Further, we will investigate whether treatment can be tailored based on the predicted risk level.

Nyheter från KI

Kalenderhändelser från KI